Clinical variables, such as tumor stage, driver mutations, carcinoembryonic antigen (CEA) levels, and histopathological characteristics, were assessed for their predictive capabilities for MRD positivity and disease relapse. This evidence concerns the gene CEACAM5 and neoplasm.